- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07376577
Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During ERCP (Anricofen Cipr)
Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During Endoscopic Retrograde Cholangiopancreatography: A Randomized Controlled Trial
This study aims to compare postoperative recovery quality and safety between anricofen combined with ciprofol and sufentanil combined with ciprofol in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) under non-intubated anesthesia.
This is a single-center, prospective, randomized, controlled study involving patients aged 18-80 years who are scheduled for elective ERCP. A total of 180 participants are planned to be enrolled and randomly assigned in a 1:1 ratio to two groups.
Participants in the anricofen group will receive intravenous anricofen (HSK21542) at a dose of 1 μg/kg before ciprofol induction. Participants in the sufentanil group will receive intravenous sufentanil at a dose of 0.1 μg/kg before ciprofol induction. Both groups will receive ciprofol for anesthesia induction and maintenance.
The primary outcome is the total Quality of Recovery-15 (QoR-15) score at 24 hours after the procedure. Secondary outcomes include postoperative pain scores at different time points, total ciprofol consumption, recovery time, post-anesthesia care unit stay, respiratory and hemodynamic adverse events, postoperative nausea and vomiting, and serious adverse events.
The study is expected to provide clinical evidence on the postoperative recovery quality and safety of these two analgesic regimens for patients undergoing ERCP under non-intubated anesthesia.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Longhua Guo
- Telefoonnummer: 18303733012
- E-mail: 1535732839@qq.com
Studie Locaties
-
-
Henan
-
Xinxiang, Henan, China
- Werving
- The First Affiliated Hospital of Henan Medical University
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
**Inclusion Criteria:**
- Aged 18 to 80 years;
- American Society of Anesthesiologists (ASA) physical status I to III;
- Patients scheduled to undergo elective endoscopic retrograde cholangiopancreatography (ERCP).
**Exclusion Criteria:**
- Pregnancy or lactation;
- Obstructive sleep apnea (OSA);
- Long-term use of analgesics or psychotropic drugs, or a history of drug abuse;
- Coagulation dysfunction, bleeding tendency, or current anticoagulant therapy;
- Allergy to any of the study drugs;
- Severe cardiac, hepatic, renal, or other major organ diseases;
- Mental or cognitive impairment that prevents cooperation with the assessment;
- Inability to comply with the study protocol or complete follow-up;
- Requirement for tracheal intubation, postoperative transfer to the intensive care unit (ICU), or postoperative pancreatitis.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Anricofen(HSK21542) 1 μg/kg + Ciprofol
|
Anricofen (HSK21542) is a peripherally restricted κ-opioid receptor agonist. In this study, it is administered intravenously at a dose of 1 μg/kg 3 minutes before ciprofol induction by slow injection. Ciprofol is an intravenous sedative agent used for anesthesia induction and maintenance in this study. It is administered intravenously at an induction dose of 0.3 mg/kg by slow injection over more than 30 seconds. After the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score reaches 3 or below, ERCP is initiated. Anesthesia is maintained with a continuous infusion of ciprofol at 1.0-2.0 mg/kg/h. If patient movement or eye opening occurs during the procedure, an additional bolus of 0.10-0.15 mg/kg may be administered, with an interval of at least 2 minutes between additional doses. |
|
Actieve vergelijker: Sufentanil 0.1 μg/kg + Ciprofol
|
Ciprofol is an intravenous sedative agent used for anesthesia induction and maintenance in this study. It is administered intravenously at an induction dose of 0.3 mg/kg by slow injection over more than 30 seconds. After the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score reaches 3 or below, ERCP is initiated. Anesthesia is maintained with a continuous infusion of ciprofol at 1.0-2.0 mg/kg/h. If patient movement or eye opening occurs during the procedure, an additional bolus of 0.10-0.15 mg/kg may be administered, with an interval of at least 2 minutes between additional doses. Sufentanil is an opioid analgesic. In this study, it is used as the active comparator and administered intravenously at a dose of 0.1 μg/kg 3 minutes before ciprofol induction by slow injection. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Quality of Recovery-15 (QoR-15) Score at 24 Hours Postoperatively
Tijdsspanne: 24 hours after the procedure
|
The primary outcome is the total score of the Quality of Recovery-15 (QoR-15) questionnaire at 24 hours after ERCP. The QoR-15 is a patient-reported measure of postoperative recovery quality, with total scores ranging from 0 to 150. Higher scores indicate better postoperative recovery quality. |
24 hours after the procedure
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Resting Numerical Rating Scale (NRS) Pain Score
Tijdsspanne: At prespecified time points postoperatively
|
Resting pain intensity will be assessed using the Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain), at the prespecified postoperative assessment time points. |
At prespecified time points postoperatively
|
|
Total Ciprofol Consumption
Tijdsspanne: During the ERCP procedure
|
The total dose of ciprofol administered to each participant during the ERCP procedure will be recorded and compared between the two groups. |
During the ERCP procedure
|
|
Respiratory and Hemodynamic Adverse Events
Tijdsspanne: During the procedure and up to 24 hours postoperatively
|
The incidence and details of perioperative respiratory and hemodynamic adverse events will be recorded. Respiratory events include hypoxemia, apnea or significant hypoventilation, airway interventions, mask-assisted ventilation, supraglottic airway placement, and emergency tracheal intubation. Hemodynamic events include hypotension, bradycardia, and the use of vasoactive drugs such as norepinephrine or atropine. |
During the procedure and up to 24 hours postoperatively
|
|
Postoperative Nausea and Vomiting (PONV)
Tijdsspanne: Within 24 hours postoperatively
|
The occurrence of postoperative nausea and vomiting will be recorded and compared between the two groups. |
Within 24 hours postoperatively
|
|
Serious Adverse Events (SAEs)
Tijdsspanne: From enrollment until the end of the study
|
The occurrence, type, and details of serious adverse events will be recorded throughout the study period. |
From enrollment until the end of the study
|
|
Recovery Time
Tijdsspanne: From the end of the ERCP procedure to recovery
|
The time required for participants to recover from anesthesia after the ERCP procedure will be recorded and compared between the two groups. |
From the end of the ERCP procedure to recovery
|
|
Post-Anesthesia Care Unit (PACU) Length of Stay
Tijdsspanne: From PACU admission to PACU discharge
|
The duration of stay in the post-anesthesia care unit (PACU) after the procedure will be recorded and compared between the two groups. |
From PACU admission to PACU discharge
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- XYFY-IIT-ANES-ERCP-2025-01
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .